--- title: "In \"The Big Banks,\" Citigroup lowered the target price for Beigene to 286.2 yuan, with last quarter's net profit falling short of expectations" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/277551795.md" description: "The Citigroup research report pointed out that Beigene's performance in the fourth quarter of 2025 was mixed, with sales increasing by 32.8% year-on-year, exceeding market expectations, but net profit fell short of expectations due to a one-time impairment. Management expects sales in 2026 to be between USD 6.2 billion and USD 6.4 billion, representing an annual growth of approximately 20%. Based on performance, the target price has been adjusted: the Hong Kong stock price has been lowered from HKD 288 to HKD 286.2, the US stock price from USD 491.2 to USD 485.1, and the A-share price from CNY 423.4 to CNY 384.5, maintaining an \"outperform\" rating" datetime: "2026-03-03T02:14:44.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/277551795.md) - [en](https://longbridge.com/en/news/277551795.md) - [zh-HK](https://longbridge.com/zh-HK/news/277551795.md) --- > 支持的语言: [English](https://longbridge.com/en/news/277551795.md) | [繁體中文](https://longbridge.com/zh-HK/news/277551795.md) # In "The Big Banks," Citigroup lowered the target price for Beigene to 286.2 yuan, with last quarter's net profit falling short of expectations Citi Research report indicates that Beigene (06160.HK) had mixed results in Q4 2025, with sales growing 32.8% year-on-year, better than market expectations. However, due to a one-time impairment, net profit fell short of expectations. Management guidance for 2026 sales is between $6.2 billion and $6.4 billion, representing an approximate 20% year-on-year growth. The firm believes there are several late-stage pipeline catalysts for the company, including BCL-2, BTK CDAC, and CDK4. After accounting for performance, the target price for Beigene's Hong Kong stock is lowered from HKD 288 to HKD 286.2, the target price for Beigene (ONC.US) in the U.S. stock market is adjusted from $491.2 to $485.1, and the target price for Beigene (688235.SH) in A-shares is reduced from RMB 423.4 to RMB 384.5; maintaining an "Outperform" rating ### 相关股票 - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md) - [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-CN/quote/159992.CN.md) - [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/zh-CN/quote/159506.CN.md) - [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/zh-CN/quote/159316.CN.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-CN/quote/IBBQ.US.md) - [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/zh-CN/quote/159102.CN.md) - [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-CN/quote/520880.CN.md) - [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-CN/quote/510660.CN.md) - [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md) - [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-CN/quote/516930.CN.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/zh-CN/quote/159859.CN.md) - [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-CN/quote/520690.CN.md) - [Guotai SSE STAR Brand Name Drug ETF (589720.CN)](https://longbridge.com/zh-CN/quote/589720.CN.md) - [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-CN/quote/588860.CN.md) - [China Southern Hang Seng Biotech ETF(QDII) (159615.CN)](https://longbridge.com/zh-CN/quote/159615.CN.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-CN/quote/159849.CN.md) - [China Universal 800 Health Care ETF (159929.CN)](https://longbridge.com/zh-CN/quote/159929.CN.md) - [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-CN/quote/516820.CN.md) - [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-CN/quote/IXJ.US.md) - [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-CN/quote/588130.CN.md) - [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-CN/quote/516500.CN.md) - [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/zh-CN/quote/513060.CN.md) - [Direxion S&P Biotech Bear 3X (LABD.US)](https://longbridge.com/zh-CN/quote/LABD.US.md) - [Beigene (BGNE.US)](https://longbridge.com/zh-CN/quote/BGNE.US.md) - [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/zh-CN/quote/588250.CN.md) - [BeOne Medicines (688235.CN)](https://longbridge.com/zh-CN/quote/688235.CN.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md) - [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md) - [Beigene (ONC.US)](https://longbridge.com/zh-CN/quote/ONC.US.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md) - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md) - [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/zh-CN/quote/560600.CN.md) - [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-CN/quote/159837.CN.md) - [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-CN/quote/512010.CN.md) - [Penghua CSI HK Connect Health Care Composite ETF (513700.CN)](https://longbridge.com/zh-CN/quote/513700.CN.md) - [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/zh-CN/quote/513120.CN.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md) - [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/zh-CN/quote/159892.CN.md) - [BEONE MEDICINES (06160.HK)](https://longbridge.com/zh-CN/quote/06160.HK.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md) ## 相关资讯与研究 - [Sanofi bets on Sino Biopharm’s transplant drug in $1.5bn licensing deal](https://longbridge.com/zh-CN/news/277818646.md) - [06:47 ETKelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Atopic Dermatitis](https://longbridge.com/zh-CN/news/278376120.md) - [MacroGenics (NASDAQ:MGNX) Announces Quarterly Earnings Results, Beats Estimates By $0.20 EPS](https://longbridge.com/zh-CN/news/278578150.md) - [03:03 ETSectra acquires Oxipit, advancing autonomous AI capabilities in diagnostic imaging](https://longbridge.com/zh-CN/news/277900089.md) - [Krystal Biotech Insider Sold Shares Worth $3,252,824, According to a Recent SEC Filing](https://longbridge.com/zh-CN/news/277754322.md)